https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e1201625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e12016252016-06-17 00:00:002016-06-17 00:00:00Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 3090)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 3090)2016-06-05 11:38:422019-07-17 11:39:065-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e11917322016-05-31 00:00:002020-11-30 10:28:30Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-11 / Cancer Res. 2016 06;76(12):3496-506
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-11 / Cancer Res. 2016 06;76(12):3496-5062016-04-11 00:00:002019-02-15 08:49:43T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-392016-02-10 00:00:002019-02-15 08:49:42Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-112016-02-01 00:00:002019-02-15 08:49:37Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-28 / Clin. Cancer Res. 2016 05;22(9):2155-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-28 / Clin. Cancer Res. 2016 05;22(9):2155-662015-12-28 00:00:002019-02-15 08:49:39Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-62015-10-01 00:00:002015-10-01 00:00:00Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-01 / PLoS ONE 2015;10(9):e0136911
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-01 / PLoS ONE 2015;10(9):e01369112015-09-01 00:00:002019-02-15 08:49:38Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)2015-06-01 11:35:202019-07-17 11:35:43Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
